Galderma announced that regulatory authorities in the European Union (EU), USA, and Canada have approved the new state-of-the-art Restylane syringe for use with the Restylane NASHA lidocaine product line for various facial and hand indications.
Approval in the EU, USA, and Canada: Indications
According to the company, the new syringe has been approved for use with the NASHA lidocaine Restylane line for several facial indications, including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, and marionette lines, as well as for the hands.
The next-generation syringe is approved for use in the EU, USA, and Canada with the NASHA lidocaine Restylane product line, including Restylane Lyft Lidocaine, Restylane Eyelight, and Restylane-L (known as Classyc Lidocaine in some markets).
What's New in the Syringe
The release highlights that the syringe features a next-generation ergonomic design that enhances precision and control, an optimized syringe-needle connection with the new Terumo K-Pack Enhance needle, and a premium syringe design with color-coded packaging for easier navigation for practitioners.
Galderma also states that the solution sets a new standard for devices in injection aesthetics and reflects the company's focus on innovation tailored to the needs of practitioners and patients.
"The development of this new syringe in close collaboration with practitioners to address their specific needs truly sets it apart. Repetitive hand movements, such as performing numerous injections daily, can lead to strain and reduced mobility, but the ergonomic design of the syringe with a soft finger support and thumb rest ensures maximum comfort during injection, supporting stable, high-quality results for patients."
Dr. Luddi Luiz Oliveira, Plastic Surgeon (Brazil).
It is noted that the syringe was developed in collaboration with over 70 practitioners in aesthetic medicine and optimized for ergonomics, aspiration ease, operational simplicity, and a premium look and feel to support practitioners in achieving premium results.
The release also emphasizes the sustainability approach: the compact cardboard packaging is 100% recyclable and, according to the company, can reduce clinic waste by up to 30% (by reducing volume).
Comment from Galderma R&D
"This next-generation syringe reflects the latest advancements in injection design, providing aesthetic medicine practitioners with superior precision, improved ergonomics, and enhanced control. By refining every element of the injector experience, we aim to help clinicians deliver consistently premium results for their patients. Through direct collaboration with practitioners, Galderma continues to push the boundaries of aesthetic innovation, and we remain steadfast in our commitment to advancing the industry."
Baldo Scassellati Sforzolini, M.D., Ph.D., Global Head of R&D, Galderma.
About the Restylane Portfolio
In the release, Galderma reminds that the Restylane portfolio consists of hyaluronic acid (HA) injectables that are "designed differently to go beyond mere volume and deliver natural-looking results." The company emphasizes that their HA is "minimally modified," and the manufacturing process maintains biocompatibility while allowing the creation of products tailored to specific goals.
Restylane is described as the "only" HA range offering four different technologies - NASHA, NASHA HD, OBT, and SB-NASHA. The release explains that the line includes both denser gels for contouring and structural support and soft, flexible formulas that smooth lines and wrinkles for a more youthful appearance.
Galderma notes that with HA "closest to the skin's own HA," the solutions are designed for personalized, natural results - with contour, definition, and hydration - to meet various patient needs in key facial, décolletage, and hand areas. The new state-of-the-art syringe is called the "next step" in the evolution of Restylane - as a "new way" to deliver familiar premium results.
About Galderma
Galderma (SIX: GALD) is a "pure-play" leader in the dermatology category, present in approximately 90 countries. The company offers an innovative, science-based portfolio of premium flagship brands and services that cover the entire spectrum of the dermatology market through Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.
Since its founding in 1981, Galderma has focused on the largest human organ - the skin - and strives to meet the individual needs of consumers and patients in partnership with healthcare professionals. The release summarizes this as the company "advancing dermatology for every skin story."